DR Reddys Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: DR Reddys Laboratories Limited Pharmaceutical Export Portfolio Dataset — 37 Products, $62.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

DR Reddys Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 37 Products, $62.4M Trade | TransData Nexus

DR Reddys Laboratories Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $62.4M Total Trade · DGFT Verified

DR Reddys Laboratories Limited is an Indian pharmaceutical exporter with a total trade value of $62.4M across 37 products in 17 therapeutic categories. Based on 1,272 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Omeprazole ($11.7M), Metoprolol ($9.6M), Diclofenac ($4.9M).

DR Reddys Laboratories Limited — Export Portfolio & Destination Treemap

DR Reddys Laboratories Limited pharmaceutical export portfolio — 37 products across 17 therapeutic categories. Source: Indian Customs (DGFT).

Who is DR Reddys Laboratories Limited? — Company Overview & Market Position

Dr. Reddy's Laboratories Limited, established in 1984 by Dr. Kallam Anji Reddy, is a prominent Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. The company operates through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's offers a diverse portfolio encompassing over 190 medications, 60 active pharmaceutical ingredients (APIs), diagnostic kits, critical care products, and biotechnology solutions.

As of March 2023, Dr. Reddy's Laboratories employed approximately 24,832 individuals. The company's stock is publicly traded on multiple exchanges, including the National Stock Exchange of India (NSE) under the ticker symbol DRREDDY, the Bombay Stock Exchange (BSE) as 500124, and the New York Stock Exchange (NYSE) as RDY.

What Does DR Reddys Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Omeprazole$11.7M 2Metoprolol

Product Portfolio — Top 30 by Export Value

DR Reddys Laboratories Limited exports 37 pharmaceutical products across 17 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Omeprazole	Gastrointestinal	$11.7M	234	1.8%	7
2	Metoprolol	Cardiovascular	$9.6M	192	1.2%	7
3	Diclofenac	Analgesics & Antipyretics	$4.9M	98	1.3%	13
4	Clopidogrel	Cardiovascular	$3.9M	78	1.6%	13
5	Fexofenadine	Antihistamines & Allergy	$3.1M	62	2.8%	6
6	Esomeprazole	Gastrointestinal	$2.9M	58	0.6%	11
7	Magnesium	Vitamins & Supplements	$2.8M	55	0.8%	10
8	Montelukast	Respiratory	$2.3M	45	1.3%	12
9	Ras	Ayurvedic & Herbal Products	$2.1M	43	0.7%	14
10	Zinc	Vitamins & Supplements	$2.0M	40	2.5%	8
11	Ondansetron	Gastrointestinal	$1.9M	58	1.6%	13
12	Valsartan	Cardiovascular	$1.4M	30	0.7%	14
13	Tacrolimus	Immunosuppressants	$1.4M	27	0.7%	9
14	Ofloxacin	Advanced Antibiotics	$1.3M	26	0.4%	2
15	Ciprofloxacin	Antibiotics	$1.1M	22	0.4%	3
16	Dexamethasone	Corticosteroids	$1.1M	22	0.6%	2
17	Naproxen	Analgesics & Antipyretics	$900.0K	18	0.7%	12
18	Rivaroxaban	Cardiovascular	$800.0K	16	1.5%	8
19	Capecitabine	Advanced Oncology	$650.0K	13	0.7%	11
20	Fulvestrant	Advanced Oncology	$650.0K	13	4.4%	4
21	Doxorubicin	Oncology	$550.0K	11	0.8%	5
22	Ephedrine	Respiratory & OTC	$550.0K	11	2.4%	5
23	Rituximab	Advanced Oncology	$550.0K	11	2.9%	3
24	Bevacizumab	Advanced Oncology	$500.0K	10	1.1%	6
25	Bortezomib	Advanced Oncology	$500.0K	10	2.3%	6
26	Bisacodyl	Gastrointestinal	$458.7K	12	5.3%	4
27	Ertapenem	Advanced Antibiotics	$450.0K	9	0.4%	6
28	Sirolimus	Immunosuppressants	$400.0K	8	2.7%	4
29	Glimepiride	Diabetes & Endocrine	$300.0K	6	0.4%	12
30	Voriconazole	Advanced Antifungals	$300.0K	6	1.0%	12

DR Reddys Laboratories Limited exports 37 pharmaceutical products across 17 therapeutic categories with a total export value of $62.4M. The top category is Gastrointestinal (27.3% of portfolio), followed by Cardiovascular (25.1%), reflecting a diversified portfolio where the top 5 products account for only 53.2% of total value.

Showing top 30 of 37 products. Contact us for complete data.

DR Reddys Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Dr. Reddy's Laboratories operates a network of manufacturing facilities across India and internationally. These facilities are equipped to produce a wide range of pharmaceutical products, including finished dosage forms and active pharmaceutical ingredients. The company's manufacturing plants adhere to stringent quality standards and are certified by various regulatory bodies, ensuring compliance with international manufacturing practices.

3Key Leadership

The leadership team at Dr. Reddy's Laboratories is headed by CEO Erez Israeli, who oversees the company's strategic direction and operations. Mannam Venkatanarasimham serves as the Chief Financial Officer, responsible for managing the company's financial strategies and performance. Other key executives include Motupalli Venkata Ramana, Chief Executive Officer of Branded Markets - India and Emerging Countries; Gunupati Venkateswara Prasad, Co-Chairman and Managing Director; and Kallam Satish Reddy, Chairman of the Board.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does DR Reddys Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Dr. Reddy's Laboratories has established a significant presence in regulated markets such as the United States, Europe, the United Kingdom, Australia, and Japan. The company has obtained approvals from regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. These approvals enable Dr. Reddy's to market and distribute its pharmaceutical products in these regions, ensuring compliance with their respective regulatory standards.

2Emerging Markets

Dr. Reddy's Laboratories has expanded its footprint into emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in several countries across these regions, facilitated by the World Health Organization's (WHO) prequalification program, which ensures that medicines meet international quality standards. This prequalification enables Dr. Reddy's to supply essential medicines to these markets, contributing to global health initiatives.

3Geographic Strategy

DR Reddys Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Dr. Reddy's Laboratories maintains several FDA-registered facilities in India and the United States. The company has received approvals for multiple Abbreviated New Drug Applications (ANDAs), allowing it to market generic versions of branded drugs in the U.S. market. Additionally, Dr. Reddy's has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes of its active pharmaceutical ingredients. The company's facilities have undergone FDA inspections, demonstrating compliance with Good Manufacturing Practices (GMP) and other regulatory requirements.

2WHO & EU GMP

Dr. Reddy's Laboratories has achieved WHO prequalification for several of its products, indicating that they meet international quality standards. The company's manufacturing facilities are certified with EU GMP, ensuring compliance with European Union regulations for pharmaceutical manufacturing. These certifications reflect Dr. Reddy's commitment to maintaining high-quality standards across its product portfolio.

3CDSCO & Indian Regulatory

DR Reddys Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Dr. Reddy's Laboratories faces competition from other major pharmaceutical companies in overlapping therapeutic categories. In the gastrointestinal segment, competitors include companies like Sun Pharma and Lupin Pharmaceuticals. In the cardiovascular segment, competitors include Torrent Pharmaceuticals and Cadila Healthcare. In the analgesics and antipyretics segment, competitors include Cipla and Glenmark Pharmaceuticals. Dr. Reddy's market share in these segments reflects its competitive positioning within the industry.

2Key Differentiators

Dr. Reddy's Laboratories differentiates itself through its comprehensive product portfolio, which includes generic drugs, over-the-counter medications, vaccines, diagnostics, biologics, and dietary supplements. The company's focus on research and development enables it to offer differentiated formulations and new chemical entities, catering to diverse therapeutic areas. Dr. Reddy's commitment to quality and regulatory compliance further strengthens its competitive advantage in the global pharmaceutical market.

3Strategic Position

Buyer Due Diligence Brief — Evaluating DR Reddys Laboratories Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Dr. Reddy's Laboratories has a strong track record in pharmaceutical manufacturing, with a consistent export volume of $62.4 million USD over the period from 2022 to 2026. The company has maintained reliability in its supply chain, ensuring timely delivery of products across various international markets. Dr. Reddy's commitment to quality and regulatory compliance further underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when sourcing from Dr. Reddy's Laboratories:

FDA Registration: Confirm that the manufacturing facility is registered with the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure that the products are manufactured in facilities certified by the World Health Organization's Good Manufacturing Practices.

EU GMP Certification: Verify that the manufacturing facility complies with European Union Good Manufacturing Practices.

Frequently Asked Questions — DR Reddys Laboratories Limited

How many pharmaceutical products does DR Reddys Laboratories Limited export from India?

DR Reddys Laboratories Limited exports 37 pharmaceutical products across 17 therapeutic categories. The top exports are Omeprazole ($11.7M), Metoprolol ($9.6M), Diclofenac ($4.9M), Clopidogrel ($3.9M), Fexofenadine ($3.1M). Total export value is $62.4M.

What is DR Reddys Laboratories Limited's total pharmaceutical export value?

DR Reddys Laboratories Limited's total pharmaceutical export value is $62.4M, based on 1,272 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does DR Reddys Laboratories Limited cover?

DR Reddys Laboratories Limited exports across 17 therapeutic categories. The largest are Gastrointestinal (27.3%, 4 products), Cardiovascular (25.1%, 4 products), Analgesics & Antipyretics (9.3%, 2 products).

Get Full DR Reddys Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.